Introduction
============

Colorectal cancer (CRC) is the third most common malignant tumor in the world, and has a relatively poor prognosis ([@b1-etm-0-0-3588]). CRC has been strongly associated with lifestyle factors, such as high intake of fat, alcohol or red meat, obesity, smoking and a lack of physical exercise, and accounts for 8% of all cancer-related mortalities, making it the most common malignancy in developed countries ([@b2-etm-0-0-3588]) and the fourth most common cause of tumor associated mortality ([@b3-etm-0-0-3588]). Although chemoprevention or chemotherapy drugs may be a promising approach to reduce the incidence and improve the prognosis of CRC, the clinical application is greatly limited by the development of chemotherapy resistance and the toxic side effects ([@b4-etm-0-0-3588],[@b5-etm-0-0-3588]). The development of CRC involves various genetic and molecular changes in cell proliferation, survival and differentiation, resistance to apoptosis, metastasis and tumor angiogenesis ([@b6-etm-0-0-3588]). Understanding the etiology of CRC is critical for the treatment of the disease. In recent years, a number of genes, including *DPYD* ([@b7-etm-0-0-3588]), *UGT1A1* ([@b8-etm-0-0-3588]) and obesity-related genes ([@b9-etm-0-0-3588]), have been found to be correlated with the progression of CRC.

Collapsin response mediator protein 4 (CRMP-4) is one of the five members of the CRMP family (CRMP 1--5), which are cytosolic phosphoproteins that are highly expressed in developing human neuronal systems ([@b10-etm-0-0-3588]). CRMP-4 regulates myelin-dependent axon outgrowth via interaction with glycogen synthase kinase-3β, as well as dendrite bifurcation of hippocampal pyramidal neurons ([@b11-etm-0-0-3588]--[@b13-etm-0-0-3588]). Recently, CRMP-4 has been reported to be associated with the proliferation, apoptosis, differentiation and invasion of numerous types of cancer cell, such as prostate ([@b14-etm-0-0-3588]) and pancreatic cancer ([@b15-etm-0-0-3588]). However, there are currently limited studies that assess the effects of CRMP-4 in SW480 cell proliferation and CRC cell growth. The aim of the present study was to explore the role of CRMP-4 in the progress of CRC, and provide a better understanding for the pathogenesis of CRC. These data may help to discover potential CRC therapeutic targets.

Materials and methods
=====================

### Materials and reagents

The human colon carcinoma cell line SW480 was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). A total of 6 nude mice (BALB/c/nu/nu strain) were obtained from the Laboratory Animal Center of Sun Yat-sen University (Guangzhou, China)). Dulbecco\'s modified Eagle\'s medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). MTT and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). A BrdU cell proliferation kit (cat. no. K306-200)was purchased from BioVision, Inc. (Milpitas, CA, USA). CRMP-4 (cat. no. 4612) and GAPDH (cat. no. 5174) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). CRMP-4 primers were synthesized by Invitrogen. Protein quantification (cat. no. YN-P0015-1) and ECL (cat. no. YN-P0017-1) kits were purchased from Guangzhou Yong-Connaught Biological Technology Co., Ltd. (Guangzhou, China). Small interfering lentivirus stable cell lines were constructed by Guangzhou Yong-Connaught Biological Technology Co., Ltd.

### Cell culture

SW480 cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin. The cells were maintained in a humidified (RH=95%) hermetic incubator (cat. no. V103002; Integrated Technologies, Ltd., Ashford, UK) with 5% CO~2~ atmosphere at 37°C. The growth of the cells was observed under an inverted microscope. The cells were subcultured at 2--4 days for one passage and all experiments were performed using cells in the logarithmic growth phase.

### Cell viability assay

Cell viability was assessed using an MTT assay. SW480 cells (1×10^4^) were seeded in 96-well culture plates at different time points and cultured for 96 h. Next, 10 µl MTT (5 mg/ml) was added to each well and further incubated for 4 h. Subsequently, the supernatant was removed and 100 µl/well DMSO was added to terminate the reaction. Absorbance was measured using a SpectraMax Plus 384 microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA) at a wavelength of 570 nm. Cell proliferation was detected using a BrdU proliferation kit in accordance with the manufacturer\'s instructions, and positive BrdU-labeled cells were thus detected.

### Reverse transcription-quantitative polymerase chain reaction (RT-PCR) analysis

Cellular mRNA was isolated from cultured SW480 cells and reversed transcribed to cDNA using a Synthesis System for RT-PCR kit (cat. no. 11904018; Invitrogen), according to the manufacturer\'s protocol. PCR amplification was performed using the following specific CRMP-4 primers: Upstream, 5′-GACCGTCTCCTTATCAAGGGA-3′; and downstream, 5′-GCATCTGGAAGTGAGTATGGAC-3′. The reaction conditions were as follows: 94°C for 5 min; 94°C for 30 sec; 60°C for 30 sec; 72°C for 45 sec (30 cycles) followed by 72°C for 10 min. The result of amplification was analyzed by 2% agarose electrophoresis. The relative expression levels of the target genes were normalized to the GAPDH internal control. All experiments were performed at least three times.

### Western blot analysis

A total of 15 patients were recruited from the First Affiliated Hospital of Sun Yat-sen University, patients who were diagnosed with colorectal cancer and had not received any chemotherapy or radiotherapy prior to surgery. From these patients, 50-mg CRC tissue samples were homogenized in 150 µl RIPA lysis buffer (Thermo Fisher Scientific, Inc.). Following centrifugation at 14,000 × g for 30 min, the supernatants were collected. Next, SW480 cells were seeded (1×10^6^ cells/well) in 6-well culture plates and lysed with 200 µl lysis buffer, and the cell lysates were collected. The protein concentrations in supernatants of both lysates were determined using Pierce Coomassie Plus (Bradford) Assay Reagent (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions. Aliquots of lysates were boiled for 5 min and refrigerated on ice followed by centrifugation at 10,000 × g for 30 sec and resolved using 10% SDS-PAGE. Proteins (30 µg) in SDS-PAGE were electrotransferred to polyvinylidene fluoride (PVDF) membranes at 100 V for 1 h. The membranes were blocked with 0.5% (W/V) fat-free milk at room temperature for 1 h and probed with anti-CRMP-4 antibody (cat. no. ab101009; dilution 1:1,000; Abcam, Cambridge, UK) overnight at 4°C, with gentle agitation. Then, the membranes were washed with 0.1% (V/V) Tris-buffered saline and Tween 20 (Thermo Fisher Scientific, Inc.) twice and incubated with mouse anti-human IgG Fc secondary antibody (JDC-10 anti-human IgG Fc; cat. no. ab99757; dilution 1,1000) at room temperature for 1 h. The membranes were washed three times and visualized using the ECL kit. Semi-quantitative analysis was performed to analyzed protein expression.

### Immunohistochemical analysis

Immunohistochemistry was performed according to the kit manufacturer\'s protocol. Tumor sections (4 mm) were deparaffinized within xylene. Following rehydration, the sections were washed three times with phosphate-buffered saline (PBS) and for 5 min. End peroxidase activity was terminated by the addition of 3% (v/v) H~2~O~2~, then the membranes were incubated for 10 min at room temperature. After three washes with PBS, the sections were blocked with 3% bovine serum albumin (BSA; Cell Signaling Technology, Inc.) at room temperature for 5 min, followed by 4°C overnight incubation with anti-CRMP-4 antibody (dilution, 1:100). After washing three times with PBS, sections were incubated at 37°C for 2 h with secondary antibodies. Finally, sections were counterstained with hematoxylin.

### Generation of si-CRMP-4 cell line

The vector LV-008 (Guangzhou Yong-Connaught Biological Technology Co., Ltd) containing an U6 promoter was used to generate small hairpin RNAs. The following oligonucleotides were subcloned into the *Hpa*I/*Xho*I sites, small hairpin RNA of CRMP-4 (si-CRMP-4). The CRMP-4 shRNA sequences were as follows: Sense, 5′-AACTGCGGCTGCATTTGTGACATTTCAAGAGAATGTCACAAATGCAGCCGCTTTTTTCTCGAGCTCGAGAAAAAAGCGGCTGCATTT GTGACATTCTCTTGAAATGTCACAAATGCAGCCGCAGTT-3′; and antisense, 3′-CTCGAGAAAAAAGCGGCTGCATTTGTGACATTCTCTTGAAATGTCACAAATGCAGCCGCAGTT-5′. Scramble sequence (NC) was used as the control group (si-scramble), the sequence is as follows: Sense, 5′-AACTTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTTC-3′; and antisense, 3′-TTGAAAGAGGCTTGCACAGTGCAAAGTTCTCTTGCACTGTGCAAGCCTCTTAAAAAAGAGCT-5′. Lentiviral production was performed as follows; briefly, HEK 293T cells (China Center for Type Culture Collection, Wuhan, China) were co-transfected with LV-008 and packaging vectors (Guangzhou Yong-Connaught Biological Technology Co., Ltd.), and the resulting supernatant was collected after 48 and 72 h. Lentiviruses were recovered after ultracentrifugation for 1.5 h at 669 × g and 4°C using an ultracentrifuge (Optima MAX-TL; Beckman Coulter, Inc., Brea, CA, USA) SW 28 rotor and resuspended in PBS. Infectious cells were conducted using 5--10 µg/ml polybrene (Sigma-Aldrich). After 48 h, the cells were cultured in 10% DMEM with 2 µg/ml puromycin (Sigma-Aldrich) for 10--15 days to generate an si-CRMP-4 stable cell line.

### Nude mice tumor xenograft model

SW480 xenografts were established in female nu/nu BALB/c mice (age, 8 weeks; weight, 18--22 g). Mice were bred under specific pathogen-free conditions, with free access to sterilized food and drinking water, in a room with constant temperature (22°C), 50--60% relative humidity and a 12 h light/dark cycle. The rats were anesthetized (8 µg/g 4% chloral hydrate; Sigma-Aldrich) during the tumor volume experiment period, and all mice were sacrificed using 4% chloral hydrate overdose. Nude mice vaccination sites were disinfected with povidone-iodine (Sigma-Aldrich), then these mice were subcutaneously injected in the dorsal scapular region with 200 µl cell suspension (2.0×10^6^ cells) by the 6th needle. CRMP-4-knockdown cells (si-CRMP-4) and control cells (si-scramble) in 100 µl PBS were injected subcutaneously into mice. Tumors were measured once per week using vernier calipers, and tumor volumes were calculated using the following formula: Volume (mm^3^) = length × width^2^ × 0.5.

### Statistical analysis

All results are expressed as the mean ± standard deviation. One-way analysis of variance was used to analyze the significance between groups. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were done by using SPSS software (version 19.0; IBM SPSS, Amronk, NY, USA).

### Ethical standards

All human studies have been approved by Sun Yat-sen University. All human studies have been performed in accordance with the Helsinki Declaration of 1975. All persons gave their informed consent prior to their inclusion in the study.

Results
=======

### Protein expression of CRMP-4 was increased in colon tumor tissue

In order to observe the expression of CRMP-4, the normal tissue, normal adjacent tissues and tumor tissue of CRC patients after surgery were collected and detected using western blot and immunohistochemistry analysis. Western blot results showed that CRMP-4 protein was significantly increased in cancer tissues ([Fig. 1A](#f1-etm-0-0-3588){ref-type="fig"}), compared with normal and paraneoplastic colon tissue. In concurrence with the western blot results, the immunohistochemical analysis results also showed that the expression of CRMP-4 protein was significantly enhanced in cancer and interstitial tissue ([Fig. 1B](#f1-etm-0-0-3588){ref-type="fig"}).

### Effect of RNA interference (RNAi)

To validate the knockdown effect of CRMP-4 on CRC, a shRNA was designed that interfered with CRMP-4 was constructed and implanted into a lentiviral vector. The lentivirus (lv-si-CRMP-4)-interfered CRMP-4 and control virus (lv-si-scramble) were packaged and purified. SW480 cells were infected with these viruses to screen the stable cell line, respectively ([Fig. 2A](#f2-etm-0-0-3588){ref-type="fig"}). Furthermore, RT-PCR and western blot analysis were conducted to validate the knockdown efficiency of CRMP-4. As shown in [Fig. 2B](#f2-etm-0-0-3588){ref-type="fig"}, CRMP-4 mRNA and protein expression were significantly suppressed by lv-si-CRMP-4 when compared with the control cells that were infected with lv-si-scramble. These results suggested that the CRMP-4-knockdown cell line (si-CRMP-4) was successfully constructed using the lentiviral vector.

### CRMP-4 inhibited proliferation of SW480 cells

In order to investigate the effects of siRNA CRMP-4 on the proliferation in SW480 cells, the changes in cell number of the si-scramble and si-CRMP-4 cells were evaluated using an MTT assay at different time points (24, 48, 72 and 96 h, respectively). The results showed that the absorbance value of SW480 cells decreased significantly in the si-CRMP-4 cells infected with lv-si-CRMP-4 ([Fig. 3A](#f3-etm-0-0-3588){ref-type="fig"}). A BrdU incorporation experiment was also conducted to determine whether the downregulation of CRMP-4 inhibits the proliferation of SW480 cells. Similar results were obtained, indicating that the proliferation of the si-CRMP-4 cells was significantly reduced compared with the si-scramble cells ([Fig. 3B](#f3-etm-0-0-3588){ref-type="fig"}). These results suggested that the downregulation of CRMP-4 expression inhibits the proliferation of SW480 cells.

### Inhibitory effects of siRNA CRMP-4 on CRC growth in vivo

In order to detect the effects of the siRNA targeting CRMP-4 on the growth of colon tumor cells, a nude mice tumor xenograft model was constructed. Mice in different groups were subcutaneously injected with si-CRMP-4 cells or the control si-scramble cells. The results showed that the application of siRNA targeted at CRMP-4 inhibited tumor growth in a xenograft model, which was consistent with the *in vitro* experiments ([Fig. 4](#f4-etm-0-0-3588){ref-type="fig"}). These results suggested that the downregulation of CRMP-4 expression inhibits the growth of colorectal tumor size.

Discussion
==========

CRC is among the most common malignant tumors in the world ([@b16-etm-0-0-3588]). Surgery combined with radiotherapy or chemotherapy is the primary treatment for CRC ([@b17-etm-0-0-3588]), with high rates of mortality and poor prognosis ([@b2-etm-0-0-3588]). si-RNA related gene therapies have been investigated in clinical trials for various malignant cancer types ([@b18-etm-0-0-3588]) and treatment of CRC by gene therapy is a potentially emerging therapy ([@b19-etm-0-0-3588]). A central challenge of tumor gene therapy is the identification of appropriate and effective targets.

As a member of the CRMP family of cytosolic phosphoproteins, CRMP-4 serves a crucial function in the mediation of semaphorin/collapsin-induced growth cone collapse and regulating the neuronal development and myelin-dependent axon outgrowth ([@b20-etm-0-0-3588]). Differential expression of CRMP-4 has been observed in numerous types of malignancy ([@b21-etm-0-0-3588],[@b22-etm-0-0-3588]). For example, CRMP-4 was differentially expressed in pancreatic cancer tissues and CRMP-4 silencing reduced cellular invasion, which indicates that CRMP-4 is significantly associated with poor prognosis by promoting liver metastasis and may serve as a novel therapeutic target for pancreatic cancer ([@b15-etm-0-0-3588]). CRMP-4 expression was inversely associated with the lymph node metastasis of prostate cancer, and its overexpression is able to suppress the invasion ability of prostate cancer cells and inhibited tumor metastasis, which showed that CRMP-4 may provide novel mechanistic insights into metastasis and therapeutic potential for prostate cancer ([@b14-etm-0-0-3588]). Due to the central role of CRMP-4 in these reported malignant cancers, it may be critical factor in the development of CRC. Thus, the present study aimed to elucidate the association between CRMP-4 was CRC cell development.

RNAi has become a powerful tool for gene knockdown and for elucidating gene function ([@b23-etm-0-0-3588]). RNAi can induce post-transcriptional gene silencing through RNA-RNA binding and transcriptional gene through RNA-DNA binding ([@b24-etm-0-0-3588]). It has been widely speculated that shRNA-mediated gene silencing can be a reliable approach for screening gene function and drug-target identification or validation ([@b25-etm-0-0-3588]--[@b27-etm-0-0-3588]).

In the present study, western blot and immunohistochemistry were used to evaluate the expression of CRMP-4 in normal tissue, normal adjacent tissues and tumor tissue of CRC patients. The CRMP-4 gene was shown to be upregulated in cancer tissues. To further investigate whether CRMP-4 is an important factor in CRC cell proliferation, SW480 cells were cultured and cell viability were tested by MTT assay. Furthermore, the shRNAs were designed to downregulate the expression of CRMP-4 in SW480 cells, and was used for the tumor xenograft CRC nude mice model *in vivo*. In present results showed that knockdown of CRMP-4 expression using a lentivirus significantly suppressed the proliferation of the SW480 cells, and inhibited tumor growth in nude mice. A previous study showed that CRMPs may be involved in cancer invasion ([@b28-etm-0-0-3588]). Among the members in CRMPs family, CRMP-1 has been proposed to be a lung cancer invasion suppressor gene ([@b29-etm-0-0-3588]). CRMP-2, which is crucially involved in T-lymphocyte function, has been identified as a potential biomarker for colorectal carcinoma by comparative analysis of cancer cell secretomes ([@b30-etm-0-0-3588],[@b31-etm-0-0-3588]). A loss-of-function screening at high-throughput level showed that CRMP-2 is a negative regulator of p53, exhibiting oncogenic activity ([@b32-etm-0-0-3588]). In addition, in association with signaling transduction, CRMPs are potentially associated with numerous cellular activities, including proliferation and migration ([@b33-etm-0-0-3588]). As CRMP-4 has not previously been reported as a marker of CRC, the present study may offer novel insights for aiding the development of CRC therapies.

In conclusion, the knockdown of CRMP-4 by lentivirus is able to suppress the proliferation of SW480 cells and the growth rate of CRC *in vivo*. These results suggest that CRMP-4 may be a potential biomarker for use in CRC treatment. In particular, gene therapy for CRC using RNAi technology based on CRMP-4 targeting may be of value and requires further investigation.
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![Expression of CRMP-4 in colorectal cancer and control tissues. (A) Western blot analysis of the protein expression of CRMP-4 in tissues from three patients and three healthy individuals, with GAPDH used as a loading control. Data obtained from three independent experiments were normalized against GAPDH and are expressed as the mean ± standard deviation, as analyzed with one-way analysis of variance. (B) Immunohistochemical analysis of the expression of CRMP-4 in tissues (stain, hematoxylin; magnification, ×100). \*P\<0.05 vs. the N group. CRMP-4, collapsin response mediator protein 4; N: normal colon tissue from healthy persons, A: normal adjacent tissues of colorectal cancer, C: colorectal cancer tissue.](etm-12-04-2003-g00){#f1-etm-0-0-3588}

![Verification of knockdown CRMP-4 expression by lentivirus. (A) SW480 cells infected with lentivirus. (B) Reverse transcription-polymerase chain reaction and western blot analysis. GAPDH was used as an internal control. CRMP-4, collapsin response mediator protein 4; lv-si-CRMP-4, SW480 cells infected with lv-si-CRMP-4 lentivirus; lv-si-scramble, SW480 cells infected with lv-si-scramble lentivirus.](etm-12-04-2003-g01){#f2-etm-0-0-3588}

![Downregulation of CRMP-4 inhibits the proliferation of SW480 cells. (A) Viability of SW480 cells were evaluated by MTT assay. (B) Proliferation of SW480 cells were evaluated by BrdU incorporation. Data were obtained from three independent experiments and are expressed as the mean ± standard deviation, as analyzed using one-way analysis of variance. \*P\<0.05 vs. the si-CRMP-4 group at the same time point. CRMP-4, collapsin response mediator protein 4; OD, optical density.](etm-12-04-2003-g02){#f3-etm-0-0-3588}

![Colon tumor sizes in each group. (A) Colon tumor of mice injected with si-scramble cells or si-CRMP-4 cells after 4 weeks of injection. (B) Colon tumor size in each group after lentivirus injection at 1, 2, 3 and 4 weeks, respectively. Data were obtained from three independent experiments and are expressed as the mean ± standard deviation, as analyzed using one-way analysis of variance. \*P\<0.05 vs. the si-CRMP-4 group at the same time point. CRMP-4, collapsin response mediator protein 4.](etm-12-04-2003-g03){#f4-etm-0-0-3588}
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